Plasma DPP4 Activity is Associated with No-reflow and Major Bleeding Events in Chinese PCI-treated STEMI Patients

Overview

Journal Sci Rep

Specialty Science

Date 2016 Dec 22

PMID 28000723

Citations 6

Authors

Jing Wei Li

Yun Dai Chen

Wei Ren Chen

Jing Jing

Jie Liu

Yong Qiang Yang

Affiliations

Soon will be listed here.

Abstract

Dipeptidyl peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and it is involved in the pathophysiological process of myocardial infarction (MI). This study investigated the role of plasma DPP4 activity (DPP4a) in patients with ST-segment elevation myocardial infarction (STEMI) who had undergone percutaneous coronary intervention (PCI). We recruited 747 consecutive PCI-treated STEMI patients from a tertiary referral center from January 2014 to October 2015. The outcomes of interest were the rates of no-reflow, in-hospital major adverse cardiac or cerebrovascular events (iMACCE), in-hospital complications (IHC) and in-hospital major bleeding. The DPP4a was lower in STEMI patients compared with the controls (p < 0.0001). Multivariate logistic-regression analyses (adjusted for confounding variables) showed that a 1 U/L increase in DPP4a was associated with an increased rate of no-reflow events (odds ratio [OR]: 1.07; 95% CI: 1.02-1.11; p < 0.01) and a decreased rate of major bleeding events (OR: 0.90; 95% CI: 0.82-0.98; p = 0.02). There were no associations between DPP4a and either iMACCE or IHC. In conclusions, high levels of DPP4a are independently associated with an increased rate of no-reflow events and a decreased rate of major bleeding events in PCT-treated STEMI patients.

Citing Articles

The predictive value of the neutrophil/platelet ratio on in-hospital adverse events and long-term prognosis in patients with coronary artery disease after percutaneous coronary intervention and its possible internal mechanism.

Xiang Y, Zeng J, Lin X, Cai X, Zhang L, Luo M Mol Cell Biochem. 2023; 479(11):3011-3019.

PMID: 38129626 DOI: 10.1007/s11010-023-04901-1.

Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study.

Kadoglou N, Korakas E, Lampropoulos S, Maratou E, Kassimis G, Patsourakos N Cardiovasc Diabetol. 2021; 20(1):166.

PMID: 34389003 PMC: 8362239. DOI: 10.1186/s12933-021-01355-x.

Saponins Protect Myocardial Ischemia Reperfusion No-Reflow Through Inhibiting the Activation of NLRP3 Inflammasome via TLR4/MyD88/NF-κB Signaling Pathway.

Yu P, Li Y, Fu W, Li X, Liu Y, Wang Y Front Pharmacol. 2021; 11:607813.

PMID: 33628178 PMC: 7898550. DOI: 10.3389/fphar.2020.607813.

Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery.

Noels H, Theelen W, Sternkopf M, Jankowski V, Moellmann J, Kraemer S Sci Rep. 2018; 8(1):11820.

PMID: 30087386 PMC: 6081383. DOI: 10.1038/s41598-018-30235-w.

Plasma dipeptidyl-peptidase-4 activity is associated with left ventricular systolic function in patients with ST-segment elevation myocardial infarction.

Li J, Chen Y, Liu Y, Wang J, Chen W, Zhang Y Sci Rep. 2017; 7(1):6097.

PMID: 28733630 PMC: 5522492. DOI: 10.1038/s41598-017-06514-3.

References

Ansorge S, Nordhoff K, Bank U, Heimburg A, Julius H, Breyer D . Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem. 2011; 392(3):153-68. DOI: 10.1515/BC.2011.008. View

Chen W, Hu S, Chen Y, Zhang Y, Qian G, Wang J . Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2015; 170(5):845-54. DOI: 10.1016/j.ahj.2015.07.014. View

OGara P, Kushner F, Ascheim D, Casey Jr D, Chung M, de Lemos J . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012; 61(4):485-510. DOI: 10.1016/j.jacc.2012.11.018. View

Zhong J, Gong Q, Goud A, Srinivasamaharaj S, Rajagopalan S . Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials. J Diabetes Res. 2015; 2015:606031. PMC: 4446505. DOI: 10.1155/2015/606031. View

Zhou H, Yang J, Xin T, Li D, Guo J, Hu S . Exendin-4 protects adipose-derived mesenchymal stem cells from apoptosis induced by hydrogen peroxide through the PI3K/Akt-Sfrp2 pathways. Free Radic Biol Med. 2014; 77:363-75. DOI: 10.1016/j.freeradbiomed.2014.09.033. View

Zhou H, Li D, Shi C, Xin T, Yang J, Zhou Y . Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro. Sci Rep. 2015; 5:12898. PMC: 4528192. DOI: 10.1038/srep12898. View

Aghili N, Devaney J, Alderman L, Zukowska Z, Epstein S, Burnett M . Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis. Neuropeptides. 2012; 46(6):367-71. DOI: 10.1016/j.npep.2012.10.001. View

Resnic F, Wainstein M, Lee M, Behrendt D, Wainstein R, Ohno-Machado L . No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003; 145(1):42-6. DOI: 10.1067/mhj.2003.36. View

Zhong J, Maiseyeu A, Davis S, Rajagopalan S . DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015; 116(8):1491-504. PMC: 4394189. DOI: 10.1161/CIRCRESAHA.116.305665. View

10.

Shah Z, Kampfrath T, Deiuliis J, Zhong J, Pineda C, Ying Z . Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011; 124(21):2338-49. PMC: 4224594. DOI: 10.1161/CIRCULATIONAHA.111.041418. View

11.

Zheng T, Yang L, Liu Y, Liu H, Yu J, Zhang X . Plasma DPP4 Activities Are Associated With Osteoporosis in Postmenopausal Women With Normal Glucose Tolerance. J Clin Endocrinol Metab. 2015; 100(10):3862-70. DOI: 10.1210/jc.2015-2233. View

12.

Wu S, Hopper I, Skiba M, Krum H . Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014; 32(4):147-58. DOI: 10.1111/1755-5922.12075. View

13.

Connelly K, Zhang Y, Advani A, Advani S, Thai K, Yuen D . DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther. 2012; 31(5):259-67. DOI: 10.1111/1755-5922.12005. View

14.

Chen W, Tian F, Chen Y, Wang J, Yang J, Wang Z . Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol. 2016; 208:109-14. DOI: 10.1016/j.ijcard.2015.12.009. View

15.

Mahmud E, Ramsis M, Behnamfar O, Enright K, Huynh A, Kaushal K . Effect of Serum Fibrinogen, Total Stent Length, and Type of Acute Coronary Syndrome on 6-Month Major Adverse Cardiovascular Events and Bleeding After Percutaneous Coronary Intervention. Am J Cardiol. 2016; 117(10):1575-1581. DOI: 10.1016/j.amjcard.2016.02.032. View

16.

Rohrborn D, Eckel J, Sell H . Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 2014; 588(21):3870-7. DOI: 10.1016/j.febslet.2014.08.029. View

17.

Mentlein R, HEYMANN E . Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers. Arch Biochem Biophys. 1982; 217(2):748-50. DOI: 10.1016/0003-9861(82)90556-2. View

18.

De Caterina R, Madonna R, Sourij H, Wascher T . Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010; 31(13):1557-64. DOI: 10.1093/eurheartj/ehq162. View

19.

Consuegra-Sanchez L, Melgarejo-Moreno A, Galcera-Tomas J, Alonso-Fernandez N, Diaz-Pastor A, Escudero-Garcia G . Impact of previous vascular burden on in-hospital and long-term mortality in patients with ST-segment elevation myocardial infarction. Rev Esp Cardiol (Engl Ed). 2014; 67(6):471-8. DOI: 10.1016/j.rec.2013.10.017. View

20.

Levine G, Bates E, Blankenship J, Bailey S, Bittl J, Cercek B . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular.... Circulation. 2011; 124(23):2574-609. DOI: 10.1161/CIR.0b013e31823a5596. View